4.6 Article

Cross-national epidemiology of panic disorder and panic attacks in the world mental health surveys

期刊

DEPRESSION AND ANXIETY
卷 33, 期 12, 页码 1155-1177

出版社

WILEY
DOI: 10.1002/da.22572

关键词

anxiety; anxiety disorders; assessment; diagnosis; epidemiology; international; panic attacks; agoraphobia

资金

  1. National Institute of Mental Health
  2. NIMH [R01 MH070884]
  3. John D. and Catherine T. MacArthur Foundation
  4. Pfizer Foundation
  5. US Public Health Service [R13-MH066849, R01-MH069864, R01 DA016558]
  6. Fogarty International Center [FIRCA R03-TW006481]
  7. Pan American Health Organization
  8. Eli Lilly and Company
  9. Ortho-McNeil Pharmaceutical
  10. GlaxoSmithKline
  11. Bristol-Myers Squibb
  12. State of Sao Paulo Research Foundation (FAPESP) Thematic Project [03/00204-3]
  13. Ministry of Health
  14. National Center for Public Health Protection
  15. Shenzhen Bureau of Health
  16. Shenzhen Bureau of Science, Technology, and Information
  17. Ministry of Social Protection
  18. Center for Excellence on Research in Mental Health (CES University)
  19. Secretary of Health of Medellin
  20. European Commission [QLG5-1999-01042, SANCO 2004123, EAHC 20081308]
  21. Piedmont Region (Italy)
  22. Fondo de Investigacion Sanitaria
  23. Instituto de Salud Carlos III, Spain [FIS 00/0028]
  24. Ministerio de Ciencia y Tecnologia, Spain [SAF 2000-158CE]
  25. Departament de Salut, Generalitat de Catalunya, Spain
  26. Instituto de Salud Carlos III [CIBER CB06/02/0046, RETICS RD06/0011 REM-TAP]
  27. United Nations Development Group Iraq Trust Fund (UNDGITF)
  28. Japan Ministry of Health, Labour and Welfare [H13-SHOGAI-023, H14-TOKUBETSU026, H16-KOKORO-013]
  29. Lebanese Ministry of Public Health
  30. WHO (Lebanon)
  31. National Institute of Health/Fogarty International Center [R03 TW006481-01]
  32. Sheikh Hamdan Bin Rashid Al Maktoum Award for Medical Sciences
  33. AstraZeneca
  34. Eli Lilly
  35. Hikma Pharmaceuticals
  36. Janssen Cilag
  37. Lundbeck
  38. Novartis
  39. Servier
  40. National Institute of Psychiatry Ramon de la Fuente [INPRFMDIES 4280]
  41. National Council on Science and Technology [CONACyT-G30544H]
  42. Pan American Health Organization (PAHO)
  43. National Council of Science and Technology [CB-2010-01-155221]
  44. New Zealand Ministry of Health
  45. Alcohol Advisory Council
  46. Health Research Council
  47. WHO(Geneva)
  48. WHO (Nigeria)
  49. Federal Ministry of Health, Abuja, Nigeria
  50. Health AMP
  51. Social Care Research AMP
  52. Development Division of the Public Health Agency
  53. National Institute of Health of the Ministry of Health of Peru
  54. Norwegian Financial Mechanism
  55. European Economic Area Mechanism as well as Polish Ministry of Health
  56. Champalimaud Foundation
  57. Gulbenkian Foundation
  58. Foundation for Science and Technology (FCT)
  59. Ministry of Public Health (former Ministry of Health)
  60. US National Institute of Mental Health [R01-MH059575, RO1-MH61905]
  61. National Institute of Drug Abuse
  62. South African Department of Health
  63. University of Michigan
  64. Regional Health Authorities of Murcia (Servicio Murciano de Salud and Consejeria de Sanidad y Politica Social)
  65. Fundacion para la Formacion e Investigacion Sanitarias (FFIS) of Murcia
  66. National Institute of Drug Abuse (NIDA)
  67. Substance Abuse and Mental Health Services Administration (SAMHSA)
  68. Robert Wood Johnson Foundation [044708]
  69. John W. Alden Trust
  70. Medical Research Council of South Africa (MRC)
  71. VICI [91812607]
  72. Netherlands Research Foundation (NWO-ZonMW)
  73. Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [03/00204-3] Funding Source: FAPESP

向作者/读者索取更多资源

ContextThe scarcity of cross-national reports and the changes in Diagnostic and Statistical Manual version 5 (DSM-5) regarding panic disorder (PD) and panic attacks (PAs) call for new epidemiological data on PD and PAs and its subtypes in the general population. ObjectiveTo present representative data about the cross-national epidemiology of PD and PAs in accordance with DSM-5 definitions. Design and settingNationally representative cross-sectional surveys using the World Health Organization Composite International Diagnostic Interview version 3.0. ParticipantsRespondents (n = 142,949) from 25 high, middle, and lower-middle income countries across the world aged 18 years or older. Main outcome measuresPD and presence of single and recurrent PAs. ResultsLifetime prevalence of PAs was 13.2% (SE 0.1%). Among persons that ever had a PA, the majority had recurrent PAs (66.5%; SE 0.5%), while only 12.8% fulfilled DSM-5 criteria for PD. Recurrent PAs were associated with a subsequent onset of a variety of mental disorders (OR 2.0; 95% CI 1.8-2.2) and their course (OR 1.3; 95% CI 1.2-2.4) whereas single PAs were not (OR 1.1; 95% CI 0.9-1.3 and OR 0.7; 95% CI 0.6-0.8). Cross-national lifetime prevalence estimates were 1.7% (SE 0.0%) for PD with a median age of onset of 32 (IQR 20-47). Some 80.4% of persons with lifetime PD had a lifetime comorbid mental disorder. ConclusionsWe extended previous epidemiological data to a cross-national context. The presence of recurrent PAs in particular is associated with subsequent onset and course of mental disorders beyond agoraphobia and PD, and might serve as a generic risk marker for psychopathology.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据